RecruitingNCT05326295

Evaluation of Treatment Efficacy by Circulating Tumor Cell Phenotype Surveillance in Breast Cancer Patients

Surveillance of Circulating Tumor Cell Phenotype in Early Stage Breast Cancer Patients With Neoadjuvant Chemotherapy or Adjuvant Chemotherapy

Sponsor

Hunan Cancer Hospital

Enrollment

1,000 participants

Start Date

Mar 1, 2019

Study Type

OBSERVATIONAL

Conditions

Breast Neoplasms Chemotherapy Effect Neoplastic Cells, Circulating

Summary

The phenotype of circulating tumor cells (CTCs) is supposed to be significant indicator that is correlated the prognosis of breast cancer patients who have completed neoadjuvant chemotherapy, primary tumor surgery with/without adjuvant chemotherapy. The aim of this observational study is to assess the efficacy of CTCs surveillance in predicting the prognosis of breast cancer patients.

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study uses circulating tumor cell (CTC) analysis — detecting cancer cells floating in the blood — to evaluate how well treatment is working in patients with various solid tumors, as a less invasive alternative to tissue biopsies. **You may be eligible if...** - You have a solid tumor cancer being treated at the participating center - You are 18 or older - You consent to additional blood draws for CTC analysis at specified time points **You may NOT be eligible if...** - You have a blood disorder that makes blood draws unsafe - You are unable to give informed consent - You are not receiving active cancer treatment Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTCTC detection

CTCs separation and enrichment technology. Combined with the prognosis of patients with recurrence and survival time, we explored the evaluation of CTC number, cell phenotype distribution, PDL1 and FOXC2 expression on the prognosis of early stage breast cancer patients. The research results are expected to provide a new effective index and theoretical basis for evaluating the treatment efficacy of breast cancer patients.